NCT01246076View on ClinicalTrials.gov

Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

May 31, 2014

Study Completion Date

August 31, 2015

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Lenalidomide

Trial Locations (2)

63110

Washington University School of Medicine, St Louis

Unknown

Mayo Clinic Scottsdale AZ, Scottsdale

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT01246076 - Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents | Biotech Hunter | Biotech Hunter